Acoramidis hydrochloride is under clinical development by BridgeBio Pharma and currently in Pre-Registration for Familial Amyloid Cardiomyopathy. According to GlobalData, Pre-Registration drugs for Familial Amyloid Cardiomyopathy have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Acoramidis hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acoramidis hydrochloride overview
Acoramidis hydrochloride (Attruby) is a stabilizing agent. It is formulated as film coated tablets for oral route of administration. Attruby is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (attr-cm) in adults to reduce cardiovascular death and cardio vascular related hospitalization.
BBP-265 (AG-10) is under development for the treatment of familial amyloid cardiomyopathy (ATTR-CM). The drug candidate is administered through oral route in the form of tablet. It acts by targeting transthyretin protein.
It was under development for the treatment of familial amyloid polyneuropathy (FAP/hereditary transthyretin amyloidosis) and amyloidosis.
BridgeBio Pharma overview
BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company that primarily focuses on the discovery, creation, testing, and delivery of transformative medicines. The company’s major products include Acoramidis, a TTR stabilizer for transthyretin amyloidosis (ATTR), and NULIBRY (fosdenopterin), a synthetic cPMP for molybdenum cofactor deficiency (MoCD). BridgeBio’s products are used in the medical industry, specifically in the treatment of various genetic diseases and cancers. The company’s pipeline products include precision cardiorenal, mendelian, precision oncology and gene therapy. Its brands include TRUSELTIQ and NULIBRY. The company operates Canada, the US, France, Germany, Switzerland and the UK. BridgeBio is headquartered in Palo Alto, California, the US.
For a complete picture of Acoramidis hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
